Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems
- 2 January 2018
- journal article
- review article
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 50 (1) , 65-73
Abstract
An association between marijuana use and schizophrenia has been noted for decades, and the recent emergence of high-efficacy synthetic cannabinoids (SCBs) as drugs of abuse has lead to a growing number of clinical reports of persistent psychotic effects in users of these substances. The mechanisms underlying SCB-elicited pro-psychotic effects is unknown, but given the ubiquitous neuromodulatory functions of the endocannabinoid system, it seems likely that agonist actions at cannabinoid type-1 receptors (CB1Rs) might modulate the functions of other neurotransmitter systems known to be involved in schizophrenia. The present review surveys what is currently known about the interactions of CB1Rs with dopamine, serotonin, and glutamate systems, because all three of those neurotransmitters are well-established in the pathophysiology of schizophrenia and psychosis. Identification of molecular mechanisms underlying the pro-psychotic effects of SCB drugs of abuse may establish certain classes of these substances as particularly dangerous, guiding regulations to control availability of these drugs. Likewise, an understanding of the pharmacological interactions which lead to schizophrenia and psychosis subsequent to SCB exposure might guide the development of novel therapies to treat afflicted users.Keywords
This publication has 100 references indexed in Scilit:
- Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptorsProceedings of the National Academy of Sciences, 2012
- Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and SchizophreniaFrontiers in Pharmacology, 2012
- Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and ActivityPLOS ONE, 2011
- Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: Implications for endocannabinoid control of hippocampal neural plasticityNeuropharmacology, 2011
- Modulation of NMDA and AMPA-mediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cellsBrain Research, 2010
- Signaling Pathways from Cannabinoid Receptor-1 Activation to Inhibition of N-Methyl-d-Aspartic Acid Mediated Calcium Influx and Neurotoxicity in Dorsal Root Ganglion NeuronsThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Rapid modulation of spine morphology by the 5-HT2Aserotonin receptor through kalirin-7 signalingProceedings of the National Academy of Sciences, 2009
- Cannabis and psychosis/schizophrenia: human studiesEuropean Archives of Psychiatry and Clinical Neuroscience, 2009
- Brain Neuronal CB2 Cannabinoid Receptors in Drug Abuse and Depression: From Mice to Human SubjectsPLOS ONE, 2008
- Roles of phospholipase Cβ and NMDA receptor in activity‐dependent endocannabinoid releaseThe Journal of Physiology, 2007